ClinicalTrials.gg
CompletedNCT03569371Updated Sep 26, 2022Results posted

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

A Phase 2 interventional study of INCB054707 in Hidradenitis Suppurativa, sponsored by Incyte Corporation. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-26.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.

Enrollment
12th of 12
10 · median 391
Started
2018
with 1 other
Phase 2
5 of 12
1 open now
Registered
1st of 12
by date

Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 12th largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 1st registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hidradenitis Suppurativa by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis suppurativa (HS)
  • Janus kinase (JAK)
  • Janus kinase 1 (JAK1) inhibitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HS (confirmed by a dermatologist) with a disease duration of at least 6 months before screening.
  • Stable course of HS for at least 90 days before screening, as determined by the investigator.
  • HS lesions present in at least 2 distinct anatomic areas, 1 of which must be Hurley Stage II or III at screening and baseline.
  • Total AN count of at least 3 at screening and baseline.
  • Male participants must agree to use per protocol-defined criteria.

Exclusion criteria

Exclusion Criteria:

  • Women of or who are currently pregnant or lactating.
  • Presence of > 20 draining fistulas at screening and baseline.
  • Participants with concurrent conditions or history of other diseases as follows:

    • Any medical condition other than HS, as determined by the investigator, that is not adequately controlled with appropriate treatment.
    • Any other active skin disease or condition (eg, bacterial, fungal, or viral infection) that may interfere with the course, severity, or assessments of HS.
    • Active systemic viral infection or any active viral infection that, based on the investigator's clinical assessment, make the participant an unsuitable candidate for the study.
    • Current herpes zoster infection, a history of recurrent herpes zoster, a history of disseminated herpes simplex, or a history of herpes zoster.
    • History of , including lymphoma and leukemia within 5 years before baseline, other than a successfully treated nonmetastatic cutaneous squamous cell carcinoma, basal cell carcinoma, or localized carcinoma in situ of the cervix.
    • Albinism.
  • Prolonged corrected for heart rate using Fridericia's formula (QTcF), defined as ≥ 450 msec.
  • Positive test result for tuberculosis (TB) from the QuantiFERON-TB Gold test, or equivalent, at screening (or, if 2 indeterminate tests or not available, then as evaluated by a purified protein derivative test with a result of \< 5 mm of induration within 3 months of screening) or a history of active TB.
  • Positive serology test results for , , hepatitis B virus (HBV) core antibody, or (HCV antibody with positive HCV-RNA) at screening.
  • Decreased blood cell counts at screening as per protocol-defined parameters.
  • Severely impaired liver function ( Class C) or (ALT) or aspartate aminotransferase (AST) levels ≥ 1.5 × (ULN).
  • Impaired renal function with serum creatinine > 1.5 mg/dL.
  • Use of prohibited medications per protocol-defined criteria.
  • Known or suspected allergy to INCB054707 or any component of the study drug.
  • Known history of clinically significant drug or alcohol abuse in the last year prior to baseline.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    INCB054707

    Drug: INCB054707

Interventions

  • INCB054707 administered once daily orally with water without regard to food for 8 weeks.

    Also known as: Povorcitinib

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to approximately 12 weeks.

Secondary outcomes

  1. Apparent Oral Clearance of INCB054707(CL/F)

    To evaluate the systemic exposure to INCB054707.

    Time frame: Postdose Day1, week 2 and 6

  2. Apparent Oral Volume of Distribution of INCB054707(Vc/F)

    To evaluate the systemic exposure to INCB054707.

    Time frame: Postdose Day1, week 2 and 6.

  3. Absorption Constant of INCB054707 (Ka)

    Other population pharmacokinetic (PK) model parameter that the PK model may include to evaluate the systemic exposure to INCB054707.

    Time frame: Postdose Day1, week 2 and 6.

  4. Apparent Inter-compartmental Clearance(Q/F)

    Other population PK model parameter that the PK model may include to evaluate the systemic exposure to INCB054707.

    Time frame: Postdose Day1, week 2 and 6.

  5. Proportion of Participants With a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit

    An HiSCR is defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline at each visit.

    Time frame: Weeks 1,2,4,6,8 and FollowUp

  6. Proportion of Participants Achieving an AN Count of 0 to 2 at Each Visit

    The number and proportion of participants who achieved an Abscess and Inflammatory nodule count of 0 to 2 progressively.

    Time frame: Weeks 1,2,4,6,8 and FollowUp

  7. Mean Change From Baseline in the HS Pain Numeric Rating Scale (NRS) Scores at Each Visit

    The HS Pain NRS will be completed in a daily diary by participants from screening through EOS. An 11-point scale will be used to assess the worst skin pain due to HS based on a recall period of the last 24 hours. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine)

    Time frame: Weeks 1,2,4,6,8 and FollowUp

  8. Mean Change From Baseline in the Modified Sartorius Scale Score

    The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.

    Time frame: Week 8.

  9. Mean Change From Baseline in the Number of Draining Fistulas Count at Each Visit

    Draining fistulas are fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.

    Time frame: Up to approximately 12 weeks.

  10. Proportion of Participants at Each Category of Hurley Stage

    The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.

    Time frame: Baseline and Week 8.

  11. Proportion of Participants With Change From Baseline to Week 8 in Hurley Stage

    The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.

    Time frame: Week 8.

  12. Proportions of Participants in Each HS Patient Global Impression of Change (PGIC) Category

    The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse.

    Time frame: Up to approximately 12 weeks.

  13. Proportion of Participants Requiring Rescue Lesional Treatment

    Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion.

    Time frame: Up to approximately 12 weeks.

  14. Number of Interventions With Rescue Lesional Treatment

    Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion.

    Time frame: Up to approximately 12 weeks.

  15. Proportion of Participants at Each Scoring Category of the Dermatology Life Quality Index (DLQI) at Each Visit

    The DLQI is a questionnaire used to assess the symptoms and the impact of skin problems on quality of life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The meaning of DLQI scores can be categorized as follows: 0-1 = No effect at all on patient's life 2-5 = Small effect on patient's life 6-10 = Moderate effect on patient's life 11-20 = Very large effect on patient's life 21-30 = Extremely large effect on patient's life

    Time frame: Up to approximately 12 weeks.

07

Results

Posted May 20, 2020

Participant flow

The study was conducted at 4 different sites in US.

Participant flow — Overall Study
MilestoneINCB054707
Started10
Completed7
Not completed3
Withdrew: Lack of efficacy1
Withdrew: Lost to follow-up1
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after first dose of study drug.

Time frame:
Up to approximately 12 weeks.
Reported as:
Number · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsINCB054707
Number of Participants With Treatment-emergent Adverse Events (TEAEs)7
SecondaryApparent Oral Clearance of INCB054707(CL/F)

To evaluate the systemic exposure to INCB054707.

Time frame:
Postdose Day1, week 2 and 6
Reported as:
Geometric mean · L/hr
Apparent Oral Clearance of INCB054707(CL/F)
L/hrINCB054707
Apparent Oral Clearance of INCB054707(CL/F)5.07 ± 24.3
SecondaryApparent Oral Volume of Distribution of INCB054707(Vc/F)

To evaluate the systemic exposure to INCB054707.

Time frame:
Postdose Day1, week 2 and 6.
Reported as:
Geometric mean · L
Apparent Oral Volume of Distribution of INCB054707(Vc/F)
LINCB054707
Apparent Oral Volume of Distribution of INCB054707(Vc/F)227 ± 39.9
SecondaryAbsorption Constant of INCB054707 (Ka)

Other population pharmacokinetic (PK) model parameter that the PK model may include to evaluate the systemic exposure to INCB054707.

Time frame:
Postdose Day1, week 2 and 6.
Reported as:
Geometric mean · 1/hr
Absorption Constant of INCB054707 (Ka)
1/hrINCB054707
Absorption Constant of INCB054707 (Ka)0.257 ± 15.2
SecondaryApparent Inter-compartmental Clearance(Q/F)

Other population PK model parameter that the PK model may include to evaluate the systemic exposure to INCB054707.

Time frame:
Postdose Day1, week 2 and 6.
Reported as:
Geometric mean · L/hr
Apparent Inter-compartmental Clearance(Q/F)
L/hrINCB054707
Apparent Inter-compartmental Clearance(Q/F)16.2 ± 13.4
SecondaryProportion of Participants With a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit

An HiSCR is defined as at least 50% reduction in abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline at each visit.

Time frame:
Weeks 1,2,4,6,8 and FollowUp
Reported as:
Count of participants · Participants
Proportion of Participants With a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit
ParticipantsINCB054707
Week 11
Week 23
Week 43
Week 62
Week 83
Follow Up4
SecondaryProportion of Participants Achieving an AN Count of 0 to 2 at Each Visit

The number and proportion of participants who achieved an Abscess and Inflammatory nodule count of 0 to 2 progressively.

Time frame:
Weeks 1,2,4,6,8 and FollowUp
Reported as:
Count of participants · Participants
Proportion of Participants Achieving an AN Count of 0 to 2 at Each Visit
ParticipantsINCB054707
Baseline0
Week 12
Week 24
Week 44
Week 62
Week 83
Follow Up4
SecondaryMean Change From Baseline in the HS Pain Numeric Rating Scale (NRS) Scores at Each Visit

The HS Pain NRS will be completed in a daily diary by participants from screening through EOS. An 11-point scale will be used to assess the worst skin pain due to HS based on a recall period of the last 24 hours. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine)

Time frame:
Weeks 1,2,4,6,8 and FollowUp
Reported as:
Mean · Units on a Scale
Mean Change From Baseline in the HS Pain Numeric Rating Scale (NRS) Scores at Each Visit
Units on a ScaleINCB054707
Week 1-1.5 ± 1.9
Week 2-3.2 ± 2.9
Week 4-2.6 ± 2.9
Week 6-3.2 ± 3.2
Week 8-2.0 ± 1.8
Follow Up-1.8 ± 1.6
SecondaryMean Change From Baseline in the Modified Sartorius Scale Score

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other). For each area, points are awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points). The total Sartorius Scale score is the sum of the 12 regional scores. Scale scores range from 0 to infinite, with larger scores representing higher severity of HS.

Time frame:
Week 8.
Reported as:
Mean · Units on a Scale
Mean Change From Baseline in the Modified Sartorius Scale Score
Units on a ScaleINCB054707
Mean Change From Baseline in the Modified Sartorius Scale Score-13.6 ± 21.3
SecondaryMean Change From Baseline in the Number of Draining Fistulas Count at Each Visit

Draining fistulas are fistulas that drain serous or purulent fluid, either spontaneously or by gentle palpation.

Time frame:
Up to approximately 12 weeks.
Reported as:
Mean · Number of Fistulas
Mean Change From Baseline in the Number of Draining Fistulas Count at Each Visit
Number of FistulasINCB054707
Week 1-0.1 ± 0.6
Week 20.2 ± 0.4
Week 40.6 ± 1.7
Week 61.9 ± 2.9
Week 80.1 ± 1.1
Follow Up0.7 ± 2.4
SecondaryProportion of Participants at Each Category of Hurley Stage

The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.

Time frame:
Baseline and Week 8.
Reported as:
Count of participants · Participants
Proportion of Participants at Each Category of Hurley Stage
ParticipantsINCB054707
Baseline — Stage I0
Baseline — Stage II7
Baseline — Stage III3
Baseline — No HS0
Week 8 — Stage I0
Week 8 — Stage II5
Week 8 — Stage III1
Week 8 — No HS1
SecondaryProportion of Participants With Change From Baseline to Week 8 in Hurley Stage

The Hurley classification is a static score and was originally designed for selection of the appropriate treatment modality in a certain body region. The assessor determines the Hurley stage in each affected anatomical region. If more than 1 stage is present in the same region, the worst stage in that region is documented. The participant will be assigned an overall Hurley stage classification corresponding to the stage of the worst involved anatomical region. The definition of each Hurley stage is as follows: Stage I : Abscess formation, single or multiple, without sinus tracts and cicatrization (scarring). Stage II : One or more widely separated recurrent abscesses with tract formation and cicatrization (scarring). Stage III : Multiple interconnected tracts and abscesses across the entire area, with diffuse or near diffuse involvement.

Time frame:
Week 8.
Reported as:
Count of participants · Participants
Proportion of Participants With Change From Baseline to Week 8 in Hurley Stage
ParticipantsINCB054707
Baseline — No HS0
Baseline — Stage I0
Baseline — Stage II7
Baseline — Stage III3
Week 8 — No HS1
Week 8 — Stage I0
Week 8 — Stage II5
Week 8 — Stage III1
SecondaryProportions of Participants in Each HS Patient Global Impression of Change (PGIC) Category

The HS-PGIC consists of 1 self-administered item that assesses change in the severity of skin in the HS area. The participant will answer the following: Since your last visit, your HS is: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse, or (7) very much worse.

Time frame:
Up to approximately 12 weeks.
Reported as:
Count of participants · Participants
Proportions of Participants in Each HS Patient Global Impression of Change (PGIC) Category
ParticipantsINCB054707
Week 1 — 10
Week 1 — 20
Week 1 — 33
Week 1 — 45
Week 1 — 52
Week 1 — 60
Week 1 — 70
Week 2 — 10
Week 2 — 21
Week 2 — 35
Week 2 — 42
Week 2 — 51
Week 2 — 60
Week 2 — 70
Week 4 — 11
Week 4 — 21
Week 4 — 30
Week 4 — 44
Week 4 — 53
Week 4 — 60
Week 4 — 70
Week 6 — 11
Week 6 — 21
Week 6 — 32
Week 6 — 42
Week 6 — 51
Week 6 — 60
Week 6 — 70
Week 8 — 10
Week 8 — 21
Week 8 — 32
Week 8 — 43
Week 8 — 51
Week 8 — 60
Week 8 — 70
Follow Up — 10
Follow Up — 21
Follow Up — 32
Follow Up — 43
Follow Up — 50
Follow Up — 60
Follow Up — 70
SecondaryProportion of Participants Requiring Rescue Lesional Treatment

Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion.

Time frame:
Up to approximately 12 weeks.
Reported as:
Count of participants · Participants
Proportion of Participants Requiring Rescue Lesional Treatment
ParticipantsINCB054707
Week 1 — Intervention Required -Yes1
Week 1 — Intervention Required -No9
Week 2 — Intervention Required -Yes0
Week 2 — Intervention Required -No9
Week 4 — Intervention Required -Yes0
Week 4 — Intervention Required -No9
Week 6 — Intervention Required -Yes0
Week 6 — Intervention Required -No7
Week 8 — Intervention Required -Yes1
Week 8 — Intervention Required -No6
Follow Up — Intervention Required -Yes0
Follow Up — Intervention Required -No7
SecondaryNumber of Interventions With Rescue Lesional Treatment

Rescue lesional treatment is defined as immediate intervention in the event of an acutely painful lesion.

Time frame:
Up to approximately 12 weeks.
Reported as:
Mean · Interventions
Number of Interventions With Rescue Lesional Treatment
InterventionsINCB054707
Week 10.1 ± 0.32
Week 20 ± 0.00
Week 40 ± 0.00
Week 60 ± 0.00
Week 80.1 ± 0.38
Follow Up0 ± 0.00
SecondaryProportion of Participants at Each Scoring Category of the Dermatology Life Quality Index (DLQI) at Each Visit

The DLQI is a questionnaire used to assess the symptoms and the impact of skin problems on quality of life. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The meaning of DLQI scores can be categorized as follows: 0-1 = No effect at all on patient's life 2-5 = Small effect on patient's life 6-10 = Moderate effect on patient's life 11-20 = Very large effect on patient's life 21-30 = Extremely large effect on patient's life

Time frame:
Up to approximately 12 weeks.
Reported as:
Count of participants · Participants
Proportion of Participants at Each Scoring Category of the Dermatology Life Quality Index (DLQI) at Each Visit
ParticipantsINCB054707
Baseline — 0-10
Baseline — 2-51
Baseline — 6-103
Baseline — 11-202
Baseline — 21-304
Week 1 — 0-10
Week 1 — 2-52
Week 1 — 6-102
Week 1 — 11-203
Week 1 — 21-303
Week 2 — 0-10
Week 2 — 2-55
Week 2 — 6-101
Week 2 — 11-201
Week 2 — 21-302
Week 4 — 0-12
Week 4 — 2-51
Week 4 — 6-102
Week 4 — 11-203
Week 4 — 21-301
Week 6 — 0-11
Week 6 — 2-51
Week 6 — 6-102
Week 6 — 11-201
Week 6 — 21-302
Week 8 — 0-10
Week 8 — 2-53
Week 8 — 6-101
Week 8 — 11-201
Week 8 — 21-302
Follow Up — 0-10
Follow Up — 2-53
Follow Up — 6-100
Follow Up — 11-202
Follow Up — 21-302

Adverse events

Collected over Up to approximately 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
INCB0547070/10 (0%)0/10 (0%)7/10 (70%)
Most frequent other events
Most frequent other events
EventINCB054707
Upper respiratory tract infectionInfections and infestations3/10
NauseaGastrointestinal disorders1/10
FibromyalgiaMusculoskeletal and connective tissue disorders1/10
HeadacheNervous system disorders1/10
AnxietyPsychiatric disorders1/10
Night sweatsSkin and subcutaneous tissue disorders1/10
RashSkin and subcutaneous tissue disorders1/10

Baseline characteristics

Age, Continuous
Age, Continuous(Number)INCB054707
Mean40.7 ± 14.43
Sex: Female, Male
Sex: Female, Male(Participants)INCB054707
Female3
Male7
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)INCB054707
Hispanic or Latino1
Not Hispanic or Latino9
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)INCB054707
White/Caucasian6
Black/African American3
Other1
08

Study locations

4 sites
  • Investigative Site
    Los Angeles, California 90045, United States
  • Investigative Site
    Tampa, Florida 33624, United States
  • Investigative Site
    New York, New York 10065, United States
  • Investigative Site
    Hershey, Pennsylvania 17033, United States
09

References and documents

Publications

  • Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H, Howell MD, Kirby JS. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022 May;186(5):803-813. doi: 10.1111/bjd.20969. Epub 2022 Mar 6. PubMed 34978076 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Apr 2019, 9 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 9 months is below that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2018
First posted
Jun 26, 2018
StartActual
Jul 17, 2018
Primary completionActual
Apr 22, 2019
CompletionActual
Apr 22, 2019
Results first posted
May 20, 2020
Last update
Sep 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03569371
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Jul 17, 2018
Primary completion
Apr 22, 2019
Completion
Apr 22, 2019
Results posted
May 20, 2020
Last update
Sep 26, 2022

Study contacts

Kathleen Butler, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion